BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 25461239)

  • 21. Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
    Delory T; Gravier S; Le Pluart D; Gaube G; Simeon S; Davido B; Piet E; Lepeule R; Lesprit P; Lafaurie M
    Int J Antimicrob Agents; 2021 Jul; 58(1):106361. PubMed ID: 34000372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae.
    Pilmis B; Parize P; Zahar JR; Lortholary O
    Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1263-5. PubMed ID: 24691683
    [No Abstract]   [Full Text] [Related]  

  • 23. Predicting Antibiotic Resistance in Urinary Tract Infection Patients with Prior Urine Cultures.
    Dickstein Y; Geffen Y; Andreassen S; Leibovici L; Paul M
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4717-21. PubMed ID: 27216064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
    Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
    Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Noncarbapenems for the Treatment of Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Bacteria.
    White CW; Kyle JA; Deas CM; Campbell J
    South Med J; 2019 Aug; 112(8):438-443. PubMed ID: 31375841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: development of a clinical decision-making nomogram.
    García-Tello A; Gimbernat H; Redondo C; Meilán E; Arana DM; Cacho J; Dorado JF; Angulo JC
    Scand J Urol; 2018 Feb; 52(1):70-75. PubMed ID: 28893132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cefmetazole for extended-spectrum β-lactamase-producing Enterobacteriaceae in pediatric pyelonephritis.
    Araki K; Fukuoka K; Higuchi H; Aizawa Y; Horikoshi Y
    Pediatr Int; 2019 Jun; 61(6):572-577. PubMed ID: 30908807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis.
    Vardakas KZ; Tansarli GS; Rafailidis PI; Falagas ME
    J Antimicrob Chemother; 2012 Dec; 67(12):2793-803. PubMed ID: 22915465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P; Boroumand MA; Rahbar M; Douraghi M
    Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
    Sfeir MM; Askin G; Christos P
    Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
    Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
    Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ofer-Friedman H; Shefler C; Sharma S; Tirosh A; Tal-Jasper R; Kandipalli D; Sharma S; Bathina P; Kaplansky T; Maskit M; Azouri T; Lazarovitch T; Zaidenstein R; Kaye KS; Marchaim D
    Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward.
    Meini S; Laureano R; Tascini C; Arena F; Fani L; Frullini A; Passaleva MT; Roberts AT; Mannini D; Sbrana F; Ripoli A; Rossolini GM
    Eur J Intern Med; 2018 Feb; 48():50-56. PubMed ID: 29089174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
    Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of non-carbapenem antibiotics to treat severe extended-spectrum β-lactamase-producing Enterobacteriaceae infections in intensive care unit patients.
    Luyt CE; Faure M; Bonnet I; Besset S; Huang F; Junot H; Hékimian G; Schmidt M; Bréchot N; Combes A; Aubry A; Mayaux J; Chastre J
    Int J Antimicrob Agents; 2019 May; 53(5):547-552. PubMed ID: 30742956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Extended-spectrum beta-lactamase producing-enterobacteriaceae].
    Mariani-Kurkdjian P; Doit C; Bingen E
    Arch Pediatr; 2012 Nov; 19 Suppl 3():S93-6. PubMed ID: 23178141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical prediction tool for extended-spectrum β-lactamase-producing Enterobacteriaceae urinary tract infection.
    Liu H; Qiu S; Chen M; Lyu J; Yu G; Xue L
    BMC Infect Dis; 2022 Jan; 22(1):50. PubMed ID: 35027010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
    Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
    J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.